Richmond Pharmacology is pleased to confirm our participation at Swiss Biotech Day 2025, one of Europe’s leading biotechnology partnering and networking events, hosted by the Swiss Biotech Association.


With thousands of industry professionals expected to attend, this year’s event will spotlight innovation across therapeutic areas,
advanced technologies, and international clinical collaboration.


Representing Richmond Pharmacology at Swiss Biotech Day:

  • Dr Jörg Täubel, Chief Executive Officer
  • Dr Tom Ashdown, Associate Medical Director
  • Stephen Wilkinson, Business Development Manager
  • Amina Senoussi, Key Account Executive


Our team is looking forward to engaging with global biotech leaders and trial sponsors to explore partnerships in:

  • Gene editing and RNA-based therapies
  • Rare and ultra-rare disease research
  • Innovative regulatory pathways
  • Bridging studies
  • Patient-first clinical trial delivery


Whether you're advancing a novel therapy or expanding into new regions, we invite you to visit us at Stand 107 to learn how Richmond Pharmacology can support your trial goals.

For meeting requests or collaboration enquiries, please contact:
info@richmondpharmacology.com

Learn more about the event:

Latest news

Richmond Appoints Lisa Campbell as Director of Regulatory Strategy

April 23, 2025
Richmond Pharmacology is pleased to announce the appointment of Lisa Campbell as Director of Regulatory Strategy
Read more

Von Willebrand Disease Trial – First Stage of Hemab Therapeutics’ Trial Completed and New Patients Invited to Enrol

April 2, 2025
Richmond has completed dosing the first cohort of patients in Velora Pioneer, a phase 1/2 clinical trial investigating Hemab...
Read more

Events

Swiss Biotech Day 2025

5–6 May 2025
Richmond Pharmacology is pleased to confirm our participation at Swiss Biotech Day 2025
View event